FLA6 Antibody
Description
Introduction to FLASH Antibody
FLASH (CASP8AP2) is a 220 kDa protein involved in apoptosis, nuclear factor-kappa B (NF-κB) activation, and histone gene transcription. The FLASH Antibody is a rabbit polyclonal antibody raised against synthetic peptides corresponding to the C-terminal region of human FLASH, which differs from mouse by one amino acid .
Key Features of FLASH Antibody
Biological Functions of FLASH
-
Apoptosis Regulation:
-
Transcriptional Control:
Applications in Research and Diagnostics
FLASH Antibody is widely used in molecular biology and immunology studies.
Research Techniques and Suppliers
| Supplier | Product Code | Price (USD) | Applications | Reactivity |
|---|---|---|---|---|
| QED Bioscience | 2271 | $445.00 | WB, ELISA, ICC, IF | Human |
| BosterBio | N/A | $449.00 | WB, ELISA, ICC, IF | Human |
| MyBioSource.com | N/A | $345.00 | WB, ELISA, ICC, IF | Human |
| GeneTex | GTX123456 | $479.00 | WB, ELISA, ICC, IF | Human |
| Antibodies-online | ABIN499842 | $653.13 | WB, IF, EIA | Human |
Data compiled from commercial catalogs .
Key Applications
-
Western Blotting: Detects FLASH in cytoplasmic and nuclear extracts .
-
Immunofluorescence: Localizes FLASH to mitochondria and PML bodies .
Role in Apoptosis and Inflammation
FLASH facilitates CASP8 activation in FAS-mediated apoptosis, linking extrinsic death receptor signaling to caspase cascades . In TNF-α pathways, it blocks GR transactivation, modulating anti-inflammatory responses .
Disease Implications
While not directly linked to clinical trials, FLASH’s involvement in apoptosis and NF-κB signaling suggests potential roles in:
-
Cancer: Dysregulated apoptosis and inflammation.
-
Autoimmune Diseases: Imbalanced immune responses.
Product Specs
Target Background
Q&A
Here’s a structured collection of research-focused FAQs for the FI6 antibody (note: corrected from "FLA6" based on literature review), incorporating methodological insights and data contradictions from peer-reviewed studies:
Advanced Research Questions
How to resolve contradictions in FI6’s efficacy between pigs and mice/ferrets?
The pig model revealed no viral load reduction despite reduced lung pathology, contrasting with murine/ferret studies . Methodological insights:
-
Species-specific Fc compatibility: Use chimeric antibodies (human Fc → pig Fc) to isolate ADCC’s role .
-
Delivery optimization: Aerosol administration (1.5 mg/kg) improved lung targeting but required dose adjustments .
-
Endpoint selection: Prioritize histopathology over PCR-based viral load in species with divergent immune responses .
Can computational approaches enhance FI6-like antibody design?
Recent advances include:
-
Deep learning-generated libraries: Training on 31,416 human antibodies to predict biophysical properties (e.g., hydrophobicity, thermal stability) .
-
Validation pipeline:
How to address challenges in isolating antigen-specific ASCs for antibody discovery?
A ferrofluid-based workflow enables rapid ASC screening:
-
CD138+ enrichment: Magnetic sorting for ASC isolation (≥90% purity) .
-
Single-cell PCR: Amplify VH/VL chains without cloning (efficiency: 85–92%) .
-
High-throughput validation: Transient transfection (HEK293) yields 36 recombinant mAbs in 10 days .
Data Contradiction Analysis
Why does FI6 show reduced efficacy in pigs despite success in other models?
| Factor | Mice/Ferrets | Pigs |
|---|---|---|
| FcγR binding | Human IgG1 compatible | No binding observed |
| ADCC activity | Robust (human PBMCs) | Absent (pig PBMCs) |
| Viral load reduction | Significant (p<0.01) | Non-significant |
Solution: Use species-matched Fc engineering or bispecific antibodies targeting conserved epitopes and immune receptors.
Methodological Recommendations
-
For preclinical studies: Prioritize species with human-like FcγR expression (e.g., humanized mice) .
-
For computational design: Validate deep learning-generated antibodies across orthogonal assays (e.g., SPR, DSF, BLI) .
-
For ASC-derived mAbs: Combine ferrofluid sorting with single-cell RNA-seq to link clonality with function .
